focus -WSS

focus

author：hotspot 2025-10-04 11:07:36 - browse：91181

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： A new deal aims to ramp up use of AI in rehab care decisions

hotspot

WSS

Attacks on the drug industry will lead to fewer breakthroughs

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Biden calls for immediate release of Niger's president amid apparent coup

A cyberattack has disrupted hospitals and health care in several states

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

leisure time

focus

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pfizer's RSV vaccine recommended for approval in Europe

Jerome Adams on the need for new antivirals for Covid

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

After affirmative action ruling, medical educators look to 'holistic review'

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Activists slam private health insurers over coverage restrictions

Gilgo Beach: Police identify another victim in serial killing investigation

How to save PrEP access — and even expand it

Why the advice to take all your antibiotics may be wrong

entertainment

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

How Brent Saunders' Allergan experiment failed

What is artificial intelligence? Experts weigh in

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

focus

hotspot

hotspot

hotspot